All Brands Owned by Grifols, S.A.

What does Grifols do?
Grifols produces medicines derived from human blood plasma. The company collects plasma at more than 400 donation centers, fractionates it into therapeutic proteins, and sells treatments for immune deficiencies, bleeding disorders, and critical care in more than 110 countries. It also operates a transfusion diagnostics business.

Is Grifols publicly traded?
Yes. Grifols shares trade on the Spanish stock exchanges under ticker GRF, with non-voting preferred shares under GRF.P. American Depositary Receipts trade on Nasdaq under GRFS. The company is a constituent of the IBEX 35 index.

Who founded Grifols?
Hematologist Josep Antoni Grifols i Roig founded a clinical laboratory in Barcelona in 1909. His sons developed the plasma fractionation business from the 1940s onward. The founding family still holds a significant shareholding and board representation.

Where is Grifols headquartered?
Grifols is headquartered in Sant Cugat del Valles, Catalonia, Spain, just outside Barcelona. Its largest operational hub outside Spain is in Research Triangle Park, North Carolina, where subsidiary Grifols Therapeutics manufactures plasma medicines including Thrombate III.

What is Grifols' revenue?
For fiscal year 2025, Grifols reported net revenue of EUR 7,524 million, up 7.0 percent at constant currency. Adjusted EBITDA was EUR 1,825 million and group profit was EUR 402 million, more than double the prior year.

Does the Grifols family still control the company?
The family holds a substantial minority stake and board representation, giving it effective influence over strategy, but the company is publicly listed with a majority free float. A 2024 attempt by the family and Brookfield to take Grifols private was abandoned before a formal offer was made.

What happened with Gotham City Research?
In January 2024, short seller Gotham City Research accused Grifols of misreporting debt and earnings. The stock fell sharply before recovering partially. Grifols denied the claims, its auditors confirmed the accounts, and Spain's regulator fined Gotham for market manipulation in 2025.